Why Bluebird Bio (BLUE) Stock Hit a One-Year High Today

NEW YORK (TheStreet) -- Bluebird Bio  (BLUE) surged to a 52-week high of $41.77 on Monday after the company reported positive results on Saturday from its gene therapy for the blood disorder beta-thalassemia.

The company announced that two patients with the blood disorder were able to cease blood transfusions after one treatment with BlueBird's experimental gene therapy called LentiGlobin, which replaces the defective gene with a fully functional one.

The stock was up 34.73% to $35.15 at 11:56 a.m. More than 4.2 million shares had changed hands, compared to the average volume of 239,356.

Must Read: Bluebird Bio Higher on Strong Gene Therapy Study Results

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

BLUE Price Chart

BLUE Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk